The UK Competition and Markets Authority publishes full decision on excessive pricing and focuses on intention and evidence (Pfizer/Flynn)

The CMA’s decision relies heavily on evidence of the parties’ intentions in applying competition rules. On 15 June 2017, the UK Competition and Markets Authority (CMA) published the full non-confidential version of its decision to fine Pfizer and Flynn a record £84.2m for their excessive and unfair pricing of phenytoin sodium capsules (used in treating epilepsy) in the UK. The CMA’s reasoning focuses heavily on the fact that both the parties had no reasonable explanation for the price increase (for

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

Quotation

Ajit Kainth, Nathdwarawala Shachi, The UK Competition and Markets Authority publishes full decision on excessive pricing and focuses on intention and evidence (Pfizer/Flynn), 15 June 2017, e-Competitions Bulletin June 2017, Art. N° 84760

Visites 64

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues